EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Mutation‐Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi‐Strains: A Study Using Glycoprotein of LASV

Saurav Kumar Mishra, Rajesh B Patil, Amdola Tshering Sherpa, Mohammad Borhan Uddin iD, Md Harun-Or-Rashid, Muniruddin Ahmed, Turki M Dawoud, John J Georrge

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Saurav Kumar Mishra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, University of North Bengal, Darjeeling, India. Hauptthemen laut MEDLINE: Epitopes, T-Lymphocyte, Vaccinology, Epitopes, B-Lymphocyte, Mutation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of North Bengal, King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lassa virus (LASV) remains a persistent threat to public health, and to combat this, various therapeutics have been developed, but their effectiveness is limited due to the virus's strain variability. Therefore, mutation‐based reverse vaccinology approaches were implemented to formulate an epitope‐based vaccine against the LASV, considering the variability in the glycoprotein. The glycoprotein was examined to screen out the B and T cell epitopes and further examined for the immunodominant epitope activity assessment. These epitopes were mapped with the identified position to introduce variability. 2 LBL (Linear B‐cell lymphocyte), 21 MHC‐I (Major Histocompatibility Complex Class I), and 8 MHC‐II potential epitopes were considered for wild and mutated (based on the mutation mapping). The wild and mutated vaccines were separately constructed, which comprise 545 amino acids in length by adjoining B and T cell epitopes via a specific linker, and also an adjuvant, PADRE epitope, 6xHis‐Tag, was incorporated to enhance the effectiveness. The formulated vaccine showed acceptable 3D structure quality (most favoured of wild: 91.5% and mutated: 91%) and high population coverage, i.e., 94%. The docking examination of wild and mutated vaccine with toll‐like receptor 2 (TLR‐2) revealed strong binding affinity, that is, −11.1 and −19.9 kcal/mol, and remarkable stability over 100 ns simulation based on the RMSD, RMSF. The immune simulation and in silico‐assisted cloning demonstrated a robust immune response and a remarkable expression in Escherichia coli system based on the GC% (wild; 57.51 and mutated; 57.57) and similar codon adaptive index value, that is, 0.93. The integrated approach will certainly aid in designing a mutation‐based epitope‐based vaccine that may counter different strains of LASV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epitopes, T-LymphocyteVaccinologyEpitopes, B-LymphocyteMutationLassa virusGlycoproteinsViral VaccinesHumansEpitope Mapping

Stichwörter der Autor:innen

Lassa virusdockingepitopeglycoproteinmutationsimulationvaccine

Substanzen

Epitopes, T-LymphocyteEpitopes, B-LymphocyteGlycoproteinsViral Vaccines

Autor:innen und Institutionen

  • Department of Bioinformatics, University of North Bengal, Darjeeling, India.
  • Department of Pharmaceutical Chemistry, Sinhgad Technical Education Society's, Sinhgad College of Pharmacy, Pune, India.
  • Computational Biology Research Laboratory, Department of Pharmacy, Daffodil International University, Dhaka, Bangladesh.
  • School of Engineering, Macquire University, Sydney, New South Wales, Australia.
  • Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Mohammad Borhan Uddin

Förderung

  • University of North Bengal
  • King Saud University

Zitieren

APA

Mishra, S. K., Patil, R. B., Sherpa, A. T., Borhan Uddin, M., Harun-Or-Rashid, M., Ahmed, M., Dawoud, T. M., & Georrge, J. J. (2025). A Mutation‐Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi‐Strains: A Study Using Glycoprotein of LASV. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70907

Vancouver

Mishra SK, Patil RB, Sherpa AT, Borhan Uddin M, Harun-Or-Rashid M, Ahmed M, et al. A Mutation‐Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi‐Strains: A Study Using Glycoprotein of LASV. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70907

BibTeX
@article{Mishra2025,
  author = {Mishra, Saurav Kumar and Patil, Rajesh B and Sherpa, Amdola Tshering and Borhan Uddin, Mohammad and Harun-Or-Rashid, Md and Ahmed, Muniruddin and Dawoud, Turki M and Georrge, John J},
  title = {A Mutation‐Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi‐Strains: A Study Using Glycoprotein of LASV},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70907}
}
Kostenlos starten →